Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2011-03-22
2011-03-22
Myers, Carla (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S023100, C536S023500, C536S024310
Reexamination Certificate
active
07910299
ABSTRACT:
The invention relates to methods and materials involved in diagnosing SLE. More particularly, the invention relates to methods and materials involved in diagnosing SLE, diagnosing severe SLE, and assessing a mammal's susceptibility to develop severe SLE. For example, the invention provides nucleic acid arrays that can be used to diagnose SLE in a mammal. Such arrays can allow clinicians to diagnose SLE based on a simultaneous determination of the expression levels of many genes that are differentially expressed in SLE patients as compared to healthy controls.
REFERENCES:
patent: 5143854 (1992-09-01), Pirrung et al.
patent: 5744305 (1998-04-01), Fodor et al.
patent: 6905827 (2005-06-01), Wohlgemuth et al.
patent: 7026121 (2006-04-01), Wohlgemuth et al.
patent: 7118865 (2006-10-01), Behrens et al.
patent: 2003/0148298 (2003-08-01), O'Toole et al.
patent: 2004/0009479 (2004-01-01), Wohlgemuth et al.
patent: WO 00/22093 (2000-04-01), None
patent: WO 02/057414 (2002-07-01), None
patent: WO 03/090694 (2003-11-01), None
Saetre et al. Molecular Brain Research. 2004. 126: 198-206.
Einav et al. Oncogene. 2005. 1-9.
National Center for Biotechnology Information, National Library of Medicine, NIH (Bethesda, MD, USA) Sequence Revision History for GenBank Accession No. U22970, printed Apr. 13, 2010, available via url <ncbi.nlm.nih.gov/sviewer/girevhist.cgi?val=u22970>.
Alarcón et al., “Systemic Lupus Erythematosus in Three Ethnic Groups,”Arthritis Rheum., 1998, 41(7):1173-1180.
Arnett and Reveille, “Genetics of Systemic Lupus Erythematosus,”Rheum. Dis. Clin. N. Am., 1992, 18(4):865-892.
Asmal et al., “Production of Ribosome Components in Effector CD4+T Cells is Accelerated by TCR Stimulation and Coordinated by ERK-MAPK,”Immunity, 2003, 19:535-548.
Bae et al., “Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus,”Lupus, 2001, 10:405-409.
Baechler et al., “Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus,”Proc. Natl. Acad. Sci. USA, 2003, 100(5):2610-2615.
Baechler et al., “Expression levels for many genes in human peripheral blood cells are highly sensitive to ex vivo incubation,”Genes and Immunity, 2004, 5:347-353.
Bennett et al., “Interferon and Granulopoiesis Signatures in Systemic Lupus Erythematosus Blood,”J. Exp. Med., 2003, 197(6):711-723.
Bombardier et al., “Derivation of the SLEDAI. A Disease Activity Index for Lupus Patients,”Arthritis Rheum., 1992, 35(6):630-640.
Braun et al., “Type I Interferon controls the onset and severity of autoimmune manifestations inIprmice,”J. Autoimmun., 2003, 20:15-25.
Buttrum et al., “Changes in neutrophil rheology after acute ischemia and reperfusion in the rat hindlimb,”J. Lab. Clin. Med., 1996, 128(5):506-514.
Dömer and Lipsky, “Correlation of circulating CD27highplasma cells and disease activity in systemic lupus erythematosus”Lupus, 2004, 13:283-289.
Eisen et al., “Cluster analysis and display of genome-wide expression patterns,”Proc. Natl. Acad. Sci. USA, 1998, 95:14863-14868.
Gergely, Jr. et al., “Persistent Mitochondrial Hyperpolarization, Increased Reactive Oxygen Intermediate Production, and Cytoplasmic Alkalinization Characterize Altered IL-10 Signaling in Patients with Systemic Lupus Erythematosus,”J. Immunol., 2002, 169:1092-1101.
Gibson, “Simulated evolution and artificial selection,”BioSystems, 1989, 23:219-229.
Ginsburg et al., “Circulating and pokeweed mitogen-induced immunoglobulin-secreting cells in systemic lupus erythematosus,”Clin. Exp. Immunol., 1979, 35:76-88.
Gladman et al., “The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus,”Arthritis Rheum., 1996, 39(3):363-369.
Gregersen and Brehrens, “Fine mapping the phenotype in autoimmune disease: the promise and pitfalls of DNA microarray technologies,”Genes and Immunity, 2003, 4:175-176.
Harada et al., “Identification of early plasma cells in peripheral blood and their clinical significance,”Br. J. Haematol., 1996, 92:184-191.
Hay et al., “The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus,”Q. J. Med., 1993, 86:447-458.
Lau et al., “Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon,”Br. J. Rheumatol., 1992, 31:375-380.
Liang et al., “Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus,”Arthritis Rheum., 1989, 32(9):1107-1118.
Liossis et al., “Immune cell biochemical abnormalities in systemic lupus erythematosus,”Clin. Exp. Rheumatol., 1997, 15:677-684.
Lövgren et al., “Induction of Interferon-α Production in Plasmacytoid Dendritic Cells by Immune Complexes Containing Nucleic Acid Released by Necrotic or Late Apoptotic Cells and Lupus IgG,”Arthritis Rheum., 2004, 50(6):1861-1872.
Pascual et al., “The central role of dendritic cells and interferon-α in SLE,”Curr. Opin. Rheumatol., 2003, 15:548-556.
Perl et al., “Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity,”Trends Immunol., 2004, 25(7):360-367.
Petri et al., “Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study,”Arthritis Rheum., 1991, 34(8):937-944.
Rainen et al., “Stabilization of mRNA Expression in Whole Blood Samples,”Clin. Chem., 2002, 48(11):1883-1890.
Rascu et al., “Clinical Relevance of Fcγ Receptor Polymorphisms,”Ann. N.Y. Acad. Sci., 1997, 815:282-295.
Reimold et al., “Plasma cell differentiation requires the transcription factor XBP-1,”Nature, 2001, 412:300-307.
Richards et al., “Interferon-γ is required for lupus nephritis in mice treated with the hydrocarbon oil pristane,”Kidney Int., 2001, 60:2173-2180.
Rönnblom et al., “Autoimmune phenomena in patients with malignant carcinoid tumors during interferon-α treatment,”Acta Oncol., 1991, 30(4):537-540.
Santiago-Raber et al., “Type-I Interferon Receptor Deficiency Reduces Lupus-like Disease in NZB Mice,”J. Exp. Med., 2003, 197(6):777-788.
Saraste, “Oxidative Phosphorylation at thefin de siècle,”Science, 1999, 283:1488-1493.
Schur, “Genetics of systemic lupus erythematosus,”Lupus, 1995, 4:425-437.
Shaffer et al., “Blimp-1 Orchestrates Plasma Cell Differentiation by Extinguishing the Mature B Cell Gene Expression Program,”Immunity, 2002, 17:51-62.
Shaffer et al., “XBP1, Downstream of Blimp-1, Expands the Secretory Apparatus and Other Organelles, and Increases Protein Synthesis in Plasma Cell Differentiation,”Immunity, 21:81-93.
Shoenfeld et al., “Effect of Physical Effort on the White Blood Cells in Benign Familial Leukopenia,”Acta Haematol., 1981, 65:108-113.
Tan and Arnett, “Genetic factors in the etiology of systemic sclerosis and Raynaud phenomenon,”Curr. Opin. Rheumatol., 2000, 12:511-519.
Vallin et al., “Patients with systemic lupus erythematosus (SLE) have a circulating inducer of interferon-alpha (IFN-α) production acting on leucocytes resembling immature dendritic cells,”Clin. Exp. Immunol., 1999, 115:196-202.
Vyse and Kotzin, “Genetic basis of systemic lupus erythematosus,”Curr. Opin. Immunol., 1996, 8:843-851.
Wakeland et al., “Delineating the Genetic Basis of Systemic Lupus Erythematosus,”Immunity, 2001, 15:397-408.
Zhu et al., “Suppression of Autoimmune Neuritis in IFN-
Baechler Emily C.
Behrens Timothy W.
Gregersen Peter K.
Fish & Richardson P.C.
Myers Carla
Regents of the University of Minnesota
The Feinstein Institute for Medical Research
LandOfFree
Methods for diagnosing systemic lupus erythematosus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for diagnosing systemic lupus erythematosus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for diagnosing systemic lupus erythematosus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2728174